Intellectual Property Strategies for Startups: Grow and Exit

Date: April 27, 2019 @ 2:00 pm – @ 6:00 pm
Location: Hanhai BioLabs Inc., 1633 Old Bayshore Highway, Suite 280, Burlingame, CA 4010

Intellectual property (IP) rights are critical assets for biotech and pharmaceutical companies. To have a successful exit strategy in your adventure, it is important to consider how to best position and properly protect your IP from the very beginning. What can you learn from recent developments on hot technologies from an IP perspective? How should you prepare for due diligence when raising funds for your startup? 

To gain insightful knowledge about the questions above, you are very welcome to attend our legal workshop “Intellectual Property Strategies for Startups: Grow and Exit,” which will be held on April 27, 2019, at Hanhai Biolabs in Burlingame, CA.  

Registration is required to attend this workshop. Seats are limited. We sincerely invite you to register as early as possible! 

Agenda

Bing Hai is a Senior IP Counsel at Bristol-Myers Squibb Company (BMS), a global biopharmaceutical company dedicated to developing innovative medicine for treating serious diseases. She supports discovery and development efforts in various disease areas as well as business transactions such as licensing and M&A from an IP perspective. Her responsibilities include patent filing and prosecution, client counseling, freedom-to-operate analysis, IP due diligence, and agreement negotiation and drafting. She has also provided IP guidance to local commercial teams in various regions including Europe, Latin America, China, and Japan. Prior to BMS, Bing was a patent attorney at Finnegan, where she focused on patent prosecution, IP due diligence and client counseling. Bing earned her Ph.D. in biology at the University of Rochester and had a significant career as a scientist in biotech before receiving her J.D. from UC, Hastings College of the Law.

Michael Liu Su is an attorney based in Finnegan’s Palo Alto office. His practice spans both patent and trade secret matters, involving industries such as biotechnology, pharmaceuticals, chemical, medical devices, and computer technology. His litigation experience includes representing clients before state and federal trial and appellate courts, and before arbitrators. He has also successfully litigated before the Patent Trial and Appeal Board (PTAB) in post-grant proceedings that involve patent validity. He also maintains an active patent procurement and due diligence practice. In his graduate work, Mike focused on cancer research at the cellular level, specifically in the areas of cell cycles, cell migration, and cancer metastasis. Mike earned an M.S. in genome sciences from National Yang-Ming University in Taiwan and a J.D. from U.C. Berkeley, School of Law.

Yieyie Yang, Ph.D., is an attorney based in Finnegan’s Washington, D.C. office. She focuses on complex patent litigation before U.S. district courts and inter partes review (IPR) proceedings in the chemical, pharmaceutical, and biotechnological fields. She has experience representing pharmaceutical patent holders in Hatch-Waxman litigations and has drafted numerous appellant and appellee briefs for pharmaceutical clients. Yieyie also has experience in due diligence analyses of antibodies and their therapeutic uses, vaccine products, immune cell therapy products, and gene therapy products. Yieyie’s scientific background is in molecular and cancer biology. Her graduate research focused on identifying novel genes involved in axon guidance during the development of the nervous system, and her new findings were published in peer-reviewed scientific journals. During her post-doctoral research period at the Dana-Farber Cancer Institute, she studied epigenetic chromatin-remodeling complexes and identified tumor suppressor candidates that interact with oncogenes during cellular transformation and tumorigenesis. Yieyie earned a Ph.D. in molecular biology at the University of Kansas and a J.D. at George Washington University Law School.

Gavin Liu is an associate in the Silicon Valley office of Latham & Watkins. Mr. Liu’s practice focuses on commercial and intellectual property transactions for public and emerging life science companies on a wide variety of transactions including collaboration and strategic alliance agreements, licensing arrangements, joint ventures, manufacturing, supply, and distribution agreements, M&A transactions, capital markets transactions, and strategic counseling. Most recently in March of 2019, Gavin represented Daiichi Sankyo in a multi-billion dollar global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s lead antibody drug conjugate product [fam-] trastuzumab deruxtecan.

Gavin received his JD in 2014 from the University of California, Berkeley School of Law; during his time in law school, he served on the Editorial Board of the Berkeley Technology and Law Journal and is an alumni of the Samuelson Law, Technology, and Public Policy Clinic. Prior to law school, Gavin received his B.S. in Neuroscience from Duke University and worked in the labs of Allison Doupe and Michael Brainard at the Keck Center for Integrative Neuroscience at the University of California, San Francisco.